|
|
Inari Medical Inc (NASDAQ: NARI) |
|
Price: $79.9700
$0.04 
0.050%
|
| Day's High:
| $79.99
| Week Perf:
| 0.11 %
|
| Day's Low: |
$ 79.96 |
30 Day Perf: |
0.72 % |
| Volume (M): |
2,359,000 |
52 Wk High: |
$ 0.00 |
| Volume (M$): |
$ 188,649 |
52 Wk Avg: |
$0.00 |
| Open: |
$79.97 |
52 Wk Low: |
$0.00 |
|
|
| Market Capitalization (Millions $) |
4,668 |
| Shares
Outstanding (Millions) |
58 |
| Employees |
450 |
| Revenues (TTM) (Millions $) |
572 |
| Net Income (TTM) (Millions $) |
-79 |
| Cash Flow (TTM) (Millions $) |
-48 |
| Capital Exp. (TTM) (Millions $) |
13 |
Business Description
Inari Medical Inc. is a medical device company founded in 2013 and headquartered in Irvine, California. The company is dedicated to developing innovative technologies that improve the outcomes of patients with complex vascular disease. Inari Medical focuses on developing catheter-based intervention systems for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), which are the most common and serious forms of venous thromboembolism (VTE). The company's flagship product is the ClotTriever System, which is designed to remove large clot burdens from deep veins without the need for thrombolytic medication.
Inari Medical's ClotTriever System is a minimally invasive medical device that facilitates the rapid removal of large clots from deep veins in the legs. The device utilizes a vacuum-based system to physically remove the clot from the vein, which eliminates the need for thrombolytic drugs and reduces the risk of bleeding complications. The ClotTriever System is easy to use, and it can be performed in an outpatient setting with local anesthesia. This minimally invasive approach helps patients to recover more quickly and reduces the burden on hospitals.
Inari Medical has shown impressive growth in recent years, with the company's revenue increasing from $5 million in 2018 to $39 million in 2020. The company has attracted significant investment from venture capitalists, with two funding rounds raising a total of $234 million. In November 2020, Inari Medical completed an initial public offering (IPO) on the NASDAQ stock exchange, raising $156 million.
Inari Medical has also received regulatory approval from the U.S. Food and Drug Administration (FDA) for its ClotTriever System. The device was cleared for use in the United States in 2018, and further approvals have been granted in Europe, Japan, and other international markets. The company has also received several awards and recognitions for its innovation and impact on patient care.
Overall, Inari Medical is a rapidly growing medical device company that is dedicated to improving the outcomes of patients with complex vascular disease. With its innovative ClotTriever System, the company has demonstrated its ability to develop and market cutting-edge medical technologies that improve patient care, reduce healthcare costs, and enhance the quality of life for patients.
Company Address: 6001 Oak Canyon Irvine 92618 CA
Company Phone Number: 923-4747 Stock Exchange / Ticker: NASDAQ NARI
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Merger and Acquisition
Published Wed, Feb 19 2025 1:30 PM UTC
Breaking News: Stryker Acquires Inari Medical, Enhances VTE Solutions PortfolioPortage, Michigan, Feb. 19, 2025 — In a strategic maneuver aimed at expanding its foothold in the rapidly growing venous thromboembolism (VTE) market, Stryker (NYSE: SYK), a renowned leader in medical technologies, announced today the successful completion of its acquisition of Inari Medical, In...
|
| Announcement
Published Sat, Jan 18 2025 12:31 PM UTC
In a significant development within the medical sector, Stryker Corporation (NYSE: SYK) has initiated a cash tender offer for all shares of Inari Medical, Inc. (NASDAQ: NARI), valuing each share at $80.00. This announcement, made on January 17, 2025, follows a merger agreement solidified on January 6, underscoring Stryker s strategic intent to expand its operations and produ...
|
| Merger and Acquisition
Published Mon, Jan 6 2025 9:08 PM UTC
Stryker Announces Definitive Agreement to Acquire Inari Medical, Inc. Providing Entry into High-Growth Peripheral Vascular SegmentIn a significant development for the medical technology industry, Stryker Corporation (NYSE: SYK) announced on January 6, 2025, a definitive agreement to acquire Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, translating to a total...
|
| Clinical Study
Published Tue, Oct 15 2024 12:01 PM UTC
In the evolving landscape of thrombosis management, new collaborations and technological advancements are pivotal in enhancing patient outcomes. On October 15, 2024, Inari Medical, Inc. a medical device company committed to transforming the lives of patients with venous and related diseases, announced its partnership with the American Venous Forum (AVF) and the National Bloo...
|
| Announcement
Published Sun, Jun 30 2024 6:07 PM UTC
Shareholder Alert: Inari Medical Faces Class Action Lawsuit Amid Investor Concerns By In a noteworthy development that is sending ripples throughout the biotech investment community, Pomerantz LLP has announced the filing of a class action lawsuit against Inari Medical, Inc. (NASDAQ: NARI). This lawsuit signifies mounting discontent among investors concerning the companyâ€...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-1.35 $ |
| Revenues (TTM) |
9.8 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.91 $
|
| Book Value |
7.45 $
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,271,500 |
| Net
Income per Employee (TTM) |
-174,627 |
| Receivable Turnover Ratio (TTM) |
7.27 |
| Inventory Turnover Ratio (TTM) |
1.53 |
| Asset Turnover Ratio (TTM) |
0.85 |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.35 $
|
| Revenues (TTM) |
9.8 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.91 $
|
| Book Value |
7.45 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
2.05%